Andrew Egger and Jonathan Cohn give their takes on the stunning back-and-forth at the FDA over Moderna’s new mRNA flu vaccine, why the agency initially refused to even review the application, and what ...

Traditionally, vaccines protect against one particular pathogen, but in this study, Stanford Medicine researchers created a vaccine that successfully offered immunity from respiratory viruses, ...

A challenging public health policy landscape under health secretary Robert F. Kennedy has vaccine makers rethinking ...

Reversing its initial decision, the FDA has agreed to review Moderna’s messenger RNA-based influenza vaccine for approval, the company announced Wednesday. The reversal about weeks after the FDA sent ...

News you should know, including a look at Big Bear's snow totals; the latest disagreement between CBS and Stephen Colbert; and more!

Was Hims' Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what's happening with Moderna and FDA? Find out on "The Readout LOUD" podcast.

Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and ...

A bid to bring more housing to Dorchester would replace the vacant Old Dorchester American Legion Post with apartments.

The FDA plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, the latest ...

Politico has reported that the White House isn’t happy with the FDA’s recent actions surrounding vaccines, fueling public scrutiny of internal decision-making at the regulator. | Politico has reported ...

Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week. As a home editor, I'm ...